January 1, Alzheimer’s Patient Stuns Doctors After Taking This Controversial Substance

Wyatt’s Take

• A woman with advanced Alzheimer’s regained speech, memories, and independence after taking psilocybin mushrooms—but the medical establishment wants you to ignore it.
• While Big Pharma pushes expensive pills with mixed results, this natural substance showed dramatic improvements in mobility, conversation, and daily living within hours.
• Federal bureaucrats still classify psilocybin as a dangerous Schedule I drug despite growing state-level reforms and mounting evidence of therapeutic benefits.

A Japanese-American woman in her 70s shocked researchers when she suddenly regained the ability to speak and recall her life story—after living with severe Alzheimer’s disease for nearly a decade. The breakthrough came after she took two doses of psilocybin-containing mushrooms as part of a Brazilian case study.

According to a report published in Frontiers in Neuroscience, the woman had been suffering from advanced dementia for roughly five years. She could barely communicate, had lost control of basic bodily functions, and depended entirely on caregivers for daily activities like dressing and walking.

The study authors described her condition before treatment as severe cognitive impairment with very limited speech, urinary incontinence, and reduced mobility. She was effectively trapped inside her own deteriorating mind.

Then came the first dose: 5 grams of psilocybin mushrooms taken orally. The woman experienced profuse sweating and elevated body temperature, followed by what researchers called a “prolonged sleep-like state.”

What happened next stunned everyone.

Approximately 19 hours after taking the mushrooms, the patient “spontaneously initiated autobiographical conversation lasting several hours,” the researchers wrote. She began talking about her life, retrieving memories that had been locked away for years.

Over the following days and weeks, the improvements accelerated. The woman regained bladder control, started walking independently, dressed herself without help, and engaged in spontaneous conversations with family and caregivers. She smiled, made eye contact, expressed emotions, and showed humor—all things that had vanished years earlier.

A month later, she received a second 3-gram dose. The results were even more dramatic: greater speech capabilities, more facial expressions, increased walking agility, and continued independence in daily activities.

Beyond the initial sweating and elevated temperature, the patient experienced no severe or persistent side effects, researchers noted. The benefits lasted at least one month, though the study doesn’t provide longer-term follow-up data.

Of course, the medical establishment immediately jumped in with all the usual caveats. The study involved only one patient, had no control group, no standardized cognitive tests, and no brain imaging. The Alzheimer’s diagnosis wasn’t confirmed with modern biomarkers, they pointed out.

“Much more research is needed in larger, more representative study populations before any conclusions can be drawn about psilocybin’s safety and effectiveness in people living with Alzheimer’s or any other disease that causes dementia,” Courtney Kloske, director of scientific engagement at the Alzheimer’s Association in Chicago, told Fox News Digital.

Dr. Marc Siegel, Fox News senior medical analyst, said he remains “dubious” of the study’s significance because the effect was temporary and limited to one case.

“Also, there is a built-in danger of giving a hallucinogen to someone with this degree of mental impairment, because the behavioral effects are largely unpredictable and can be harmful,” Siegel said.

“Having said that, I am not surprised to see that psilocybin could temporarily overcome or alter the gummed-up [brain] circuitry (with plaques) of advanced Alzheimer’s disease – so it might have some value in a carefully controlled setting.”

The timing of this study is notable. Several states have recently expanded legal access to psilocybin, even as the federal government continues to classify it as a dangerous Schedule I substance—the same category as heroin.

Oregon began licensing psilocybin service centers in 2023. Colorado’s regulated natural medicine program became operational in 2025. New Mexico enacted a Medical Psilocybin Act last year.

Yet there are currently no FDA-approved psilocybin treatments for Alzheimer’s disease or dementia. Legal access remains limited to certain state-regulated programs or approved research settings.

Meanwhile, Big Pharma continues pushing expensive Alzheimer’s medications with questionable effectiveness and serious side effects. Two recently approved drugs—lecanemab and donanemab—cost tens of thousands of dollars per year and offer only modest cognitive benefits for some patients.

Wyatt Matters

For families watching their loved ones fade away from Alzheimer’s, this case study offers a glimmer of hope—and a stark reminder of how federal regulations often stand between Americans and potentially life-changing treatments. While bureaucrats demand more studies and more paperwork, real people are suffering. States are starting to push back against Washington’s one-size-fits-all drug policies, and that’s a good thing. Families should have the freedom to explore every possible option when facing devastating diseases like Alzheimer’s, not wait years for the FDA’s permission slip.